282 results
8-K
EX-99.2
LUMO
Lumos Pharma Inc
15 May 24
Lumos Pharma Announces Positive End-of-Phase 2 Meeting with FDA and Reports First Quarter 2024 Financial Results
9:57am
are forward- looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. This law that, in part, gives us … the opportunity to share our outlook for the future without fear of litigation if it turns out our predictions were not correct. We are passionate about our
8-K
EX-99.1
LUMO
Lumos Pharma Inc
15 May 24
Lumos Pharma Announces Positive End-of-Phase 2 Meeting with FDA and Reports First Quarter 2024 Financial Results
9:57am
contained in this press release are forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. A law that, in part … , gives us the opportunity to share our outlook for the future without fear of litigation if it turns out our predictions were not correct.
We
8-K
EX-99.1
LUMO
Lumos Pharma Inc
18 Apr 24
Lumos Pharma Announces Abstracts Accepted for Presentation at Upcoming Medical Meetings
4:53pm
in this press release are forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. A law that, in part, gives us … the opportunity to share our outlook for the future without fear of litigation if it turns out our predictions were not correct.
We are passionate about
8-K
EX-99.1
hzu az3o2v
20 Mar 24
Lumos Pharma Announces that the USPTO Has Granted Patent Protection for Novel Formulation of LUM-201, Extending Exclusivity to 2042
4:27pm
8-K
EX-99.1
eld avi3gppsq331y
7 Mar 24
Lumos Pharma Reports Full Year 2023 Financial Results and Provides Clinical Development Update
4:44pm
8-K
EX-99.2
2lqgrsh
7 Mar 24
Lumos Pharma Reports Full Year 2023 Financial Results and Provides Clinical Development Update
4:44pm
8-K
EX-99.1
36tzw
4 Jan 24
Regulation FD Disclosure
4:34pm
8-K
EX-99.1
eht87u1i
15 Nov 23
Other Events
4:38pm
8-K
EX-99.1
wkmt59deivz q7o
7 Nov 23
Lumos Pharma Reports Third Quarter 2023 Financial Results and Clinical Development Updates
4:42pm
8-K
EX-99.2
h45p6tu6t9ccepjvaif3
7 Nov 23
Lumos Pharma Announces Topline Data from Phase 2 OraGrowtH210 and OraGrowtH212 Trials of LUM-201 in PGHD
4:08pm
8-K
EX-99.1
y52y3fgm hde
7 Nov 23
Lumos Pharma Announces Topline Data from Phase 2 OraGrowtH210 and OraGrowtH212 Trials of LUM-201 in PGHD
4:08pm
8-K
EX-99.1
ersf19
26 Sep 23
Lumos Pharma Announces New Data and Analysis of 15 Subjects from OraGrowtH212 Trial Presented at the 2023 ESPE Annual Meeting
4:34pm
8-K
EX-99.1
3s0ti0c
9 Aug 23
Lumos Pharma Reports Second Quarter 2023 Financial Results, Provides Clinical Update
4:36pm
8-K
EX-99.2
qsa0zc
9 Aug 23
Lumos Pharma Reports Second Quarter 2023 Financial Results, Provides Clinical Update
4:36pm
8-K
EX-99.2
qqjj9r9nz5fhgmt
21 Jun 23
Lumos to Highlight New LUM-201 Data and Analysis Presented
5:10pm